Humoral and cellular responses after a third dose of SARS-CoV-2 BNT162b2 vaccine in patients with lymphoid malignancies.
Adult
Aged
Aged, 80 and over
Antibodies, Neutralizing
/ immunology
Antibodies, Viral
/ immunology
BNT162 Vaccine
/ administration & dosage
COVID-19
/ immunology
Female
Hematologic Neoplasms
Humans
Immunity, Cellular
/ immunology
Immunity, Humoral
/ immunology
Immunization, Secondary
/ methods
Male
Middle Aged
Multiple Myeloma
SARS-CoV-2
/ immunology
Spike Glycoprotein, Coronavirus
/ immunology
T-Lymphocytes
/ immunology
Journal
Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555
Informations de publication
Date de publication:
14 02 2022
14 02 2022
Historique:
received:
13
09
2021
accepted:
26
01
2022
entrez:
15
2
2022
pubmed:
16
2
2022
medline:
1
3
2022
Statut:
epublish
Résumé
Patients with hematological malignancies have impaired immune response after two doses of BNT162b2 (Pfizer/BioNTech) vaccine against SARS-CoV-2. Here, in this observational study (registration number HDH F20210324145532), we measure SARS-CoV-2 anti-Spike antibodies, neutralizing antibodies and T-cell responses after immune stimulation with a third dose (D3) of the same vaccine in patients with chronic lymphocytic leukemia (n = 13), B cell non-Hodgkin lymphoma (n = 14), and multiple myeloma (n = 16)). No unexpected novel side effects are reported. Among 25 patients with positive anti-S titers before D3, 23 (92%) patients increase their anti-S and neutralizing antibody titer after D3. All 18 (42%) initially seronegative patients remain negative. D3 increases the median IFN-γ secretion in the whole cohort and induces IFN-γ secretion in a fraction of seronegative patients. Our data thus support the use of a third vaccine dose amongst patients with lymphoid malignancies, even though some of them will still have vaccine failure.
Identifiants
pubmed: 35165284
doi: 10.1038/s41467-022-28578-0
pii: 10.1038/s41467-022-28578-0
pmc: PMC8844396
doi:
Substances chimiques
Antibodies, Neutralizing
0
Antibodies, Viral
0
Spike Glycoprotein, Coronavirus
0
spike protein, SARS-CoV-2
0
BNT162 Vaccine
N38TVC63NU
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
864Informations de copyright
© 2022. The Author(s).
Références
Ann Oncol. 2021 Oct;32(10):1294-1295
pubmed: 34171494
Med Clin (Barc). 2021 Sep 25;:
pubmed: 34666900
Nat Med. 2021 Jul;27(7):1280-1289
pubmed: 34017137
N Engl J Med. 2021 Aug 12;385(7):661-662
pubmed: 34161700
Leuk Lymphoma. 2021 Dec;62(13):3308-3310
pubmed: 34308748
Ann Oncol. 2021 Aug;32(8):1053-1055
pubmed: 33932508
Nat Med. 2021 Nov;27(11):1990-2001
pubmed: 34522051
Nat Med. 2021 Sep;27(9):1530-1535
pubmed: 34312554
Nature. 2021 Aug;596(7871):276-280
pubmed: 34237773
JAMA Oncol. 2021 Feb 1;7(2):220-227
pubmed: 33300956
J Clin Invest. 2021 May 17;131(10):
pubmed: 33822770
Blood. 2021 Jun 10;137(23):3165-3173
pubmed: 33861303
Am J Hematol. 2021 Aug 1;96(8):934-944
pubmed: 33909916
Front Public Health. 2021 Sep 27;9:732787
pubmed: 34646805
Eur J Cancer. 2021 Jun;150:1-9
pubmed: 33882374
Ann Oncol. 2021 Jun;32(6):787-800
pubmed: 33746047
Ann Oncol. 2021 Oct;32(10):1297-1300
pubmed: 34265373
N Engl J Med. 2021 Sep 23;385(13):1244-1246
pubmed: 34379917
JAMA. 2021 Jul 23;:
pubmed: 34297036
EClinicalMedicine. 2021 Feb;32:100734
pubmed: 33589882
Blood. 2021 Jul 1;137(26):3674-3676
pubmed: 33861315
Nat Med. 2021 Jul;27(7):1205-1211
pubmed: 34002089
Lancet Oncol. 2021 Jun;22(6):765-778
pubmed: 33930323
JAMA. 2021 Jun 1;325(21):2204-2206
pubmed: 33950155
Eur J Cancer. 2021 Sep;154:66-72
pubmed: 34243079